Zivo Bioscience Q1 Revenue Plummets, Expenses Cut
Ticker: ZIVOW · Form: 10-Q · Filed: May 15, 2025 · CIK: 1101026
| Field | Detail |
|---|---|
| Company | Zivo Bioscience, Inc. (ZIVOW) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: revenue-decline, expense-reduction, financial-results, subsequent-event
TL;DR
Zivo Bioscience Q1 revenue down to $0.001M from $3.62M, expenses slashed. Big changes afoot.
AI Summary
Zivo Bioscience, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported $0.001 million in revenue for Q1 2025, compared to $3.62 million in Q1 2024. Operating expenses were $1.10 million for Q1 2025, a decrease from $3.79 million in the prior year's quarter. The company also disclosed a subsequent event in April 2025.
Why It Matters
The significant drop in revenue and operating expenses suggests a major shift in Zivo Bioscience's operations or market conditions, potentially impacting its future growth and investor outlook.
Risk Assessment
Risk Level: high — The drastic decrease in revenue and significant reduction in operating expenses indicate potential financial distress or a strategic pivot that carries substantial risk.
Key Numbers
- $0.001M — Q1 2025 Revenue (Significant decrease from prior year)
- $3.62M — Q1 2024 Revenue (Prior year revenue for comparison)
- $1.10M — Q1 2025 Operating Expenses (Reduced from prior year)
- $3.79M — Q1 2024 Operating Expenses (Prior year operating expenses for comparison)
Key Players & Entities
- Zivo Bioscience, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- $0.001 million (dollar_amount) — Q1 2025 revenue
- $3.62 million (dollar_amount) — Q1 2024 revenue
- $1.10 million (dollar_amount) — Q1 2025 operating expenses
- $3.79 million (dollar_amount) — Q1 2024 operating expenses
- 2025-04-01 (date) — Start of subsequent event period
FAQ
What caused the drastic decrease in Zivo Bioscience's revenue from $3.62 million in Q1 2024 to $0.001 million in Q1 2025?
The filing does not explicitly state the cause for the revenue decrease, but it indicates a significant operational change.
How were operating expenses reduced from $3.79 million in Q1 2024 to $1.10 million in Q1 2025?
The filing indicates a reduction in operating expenses, but the specific measures taken are not detailed in the provided excerpt.
What is the nature of the subsequent event disclosed for April 2025?
The filing mentions a subsequent event occurring between April 1, 2025, and April 30, 2025, but the details of this event are not provided in the excerpt.
What is Zivo Bioscience's primary business according to the filing?
Zivo Bioscience, Inc. is involved in Biological Products (No Diagnostic Substances) as per its Standard Industrial Classification code [2836].
What was the company's fiscal year end?
The company's fiscal year ends on December 31st.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Zivo Bioscience, Inc. (ZIVOW).